Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
Department of Otorhinolaryngology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
J Coll Physicians Surg Pak. 2023 Feb;33(2):153-157. doi: 10.29271/jcpsp.2023.02.153.
To compare COVID-19 associated mucormycosis cases (CAM) with non-COVID-19 associated mucormycosis (non-CAM) cases followed as in-patients.
Observational Study.
Department of Infectious Diseases and Clinical Microbiology, Adana City Training and Research Hospital, Health Sciences University (HSU), Adana, Turkey, between January 2018 and March 2022.
Patients with a diagnosis of mucormycosis (proven and probable) were dichotomised as COVID-19 associated mucormycosis and non-COVID-19 associated mucormycosis cases. Both groups were compared for underlying malignancy, chemotherapy, antifungal therapy related side effects and overall survival.
Of the 35 cases enrolled in the study, 17 (48.6%) had CAM and 18 (51.4%) had non-CAM. A statistically significant difference was detected between non-CAM and CAM cases in terms of haematological malignancy, receiving chemotherapy, and antifungal therapy-related side effects (p=0.019, p=0.019, and p=0.027 respectively). Steroid use was found as a risk factor for the diabetic CAM cases (p<0.0001). The difference between the CAM and non-CAM cases in terms of overall survival was not statistically significant (p=0.088).
Because of the ongoing COVID-19 pandemic and the increasing number of critical patients, treatment of COVID-19 should be performed cautiously in patients who have the risk of developing CAM, particularly those with diabetes and immunosuppression (haematologic malignancy, receiving steroid or chemotherapy, etc.) and these patients should be monitored closely.
Mucormycosis, COVID-19, Mucormycosis associated with COVID-19, Diabetes mellitus, Turkey.
比较 COVID-19 相关毛霉病（CAM）与住院患者中非 COVID-19 相关毛霉病（非-CAM）病例。
观察性研究。
土耳其哈塔伊阿达纳市培训与研究医院传染病和临床微生物学系，健康科学大学（HSU），阿达纳，2018 年 1 月至 2022 年 3 月。
将诊断为毛霉病（确诊和可能）的患者分为 COVID-19 相关毛霉病和非 COVID-19 相关毛霉病病例。比较两组基础恶性肿瘤、化疗、抗真菌治疗相关副作用和总生存率。
在纳入研究的 35 例患者中，17 例（48.6%）为 CAM，18 例（51.4%）为非-CAM。非-CAM 和 CAM 病例在血液系统恶性肿瘤、接受化疗和抗真菌治疗相关副作用方面存在统计学显著差异（p=0.019，p=0.019，和 p=0.027 分别）。发现皮质类固醇的使用是糖尿病 CAM 病例的危险因素（p<0.0001）。CAM 和非-CAM 病例在总生存率方面的差异无统计学意义（p=0.088）。
由于 COVID-19 大流行的持续和危重症患者数量的增加，在有发生 CAM 风险的患者中，特别是那些患有糖尿病和免疫抑制（血液系统恶性肿瘤、接受皮质类固醇或化疗等）的患者中，应谨慎治疗 COVID-19，并且应密切监测这些患者。
毛霉病，COVID-19，COVID-19 相关毛霉病，糖尿病，土耳其。
